1. Novel Therapies for the Treatment of MS

3. Daclizumab: Mechanism of Action

4. SELECT: Study Results

5. DECIDE: Study Design

6. DECIDE: Study Results

7. DECIDE: Safety Data

8. DAC HYP: Safety

9. Mechanism of Action of B-Cell-Targeted Therapy in MS

10. OPERA I and II: Study Designs

11. OPERA I and OPERA II: Pooled Data Analysis

12. OPERA I and II: Study Results at 96 Weeks

13. OPERA I and II: Relative Reduction in MRI Measures With Ocrelizumab as Compared With IFN-β1a

14. OPERA I and II: Safety

15. ORATORIO: Study Design

16. ORATORIO: Risk of Disease Progression

17. ORATORIO: Safety

18. INFORMS: Study Design and Results

19. INFORMS: Impact of Baseline NBV on Likelihood of Disease Progression

20. S1P1 Modulators

21. ASCEND: Study Design

22. ASCEND: Study Results

23. Proposed Anti-LINGO MOA

24. RENEW: MF-VEP Substudy Results*

25. SYNERGY: Trial Design and Results

26. MS-SPI: Trial Design

27. MS-SPI: Subgroup Analyses

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)